India Globalization Capital

India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IGC Pharma, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Appoints Former Congressman Jim Moran to its Board of Directors.

India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of Directors

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--Clinical Trial on Alzheimer's Patients Indicates Positive Safety and Tolerability Data for IGC's THC-Based Investigational New Drug

Clinical Trial on Alzheimer's Patients Indicates Positive Safety and Tolerability Data for IGC's THC-Based Investigational New Drug

Agrify

Flora Growth Corp

GrowGeneration Corp

High Tide

Jupiter Wellness

Chicago Atlantic Real Estate Finance

Tilray Brands

The Valens Co

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

9 Hottest Stories from the Cannabis Sector This Week

POTOMAC, MD,--(BUSINESS WIRE)-- #IGC--IGC-AD1 Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer's Patients.

Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer's Patients

POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--IGC Phase 1 Clinical Trial Data Indicate IGC's THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer's Patients.

Phase 1 Clinical Trial Data Indicate IGC's THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer's Patients

India Globalization Capital, Inc. (AMEX: IGC) reported its financial results Friday for the three months ended September 30, 2021, with revenue of $56,000, compared to $125,000 in the same period of 2020. The Bethesda, Maryland-based company noted that revenues in both quarters were primarily derived from its Life Sciences segment, which involved sales of products such as lotion, gummies and alcohol-based hand sanitizers.

IGC Posts Q2 Results, Reveals Promising Results From Clinical Trial Of THC-Drug For Alzheimer's Symptoms

BETHESDA, Md.--(BUSINESS WIRE)-- #Alzheimers--IGC announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company's 2022 fiscal year.

IGC Reports Financial Results for the September 30, 2021 Quarter

POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--Voting on all matters as disclosed on the Def Proxy filed with the SEC on Sep 15'21 were passed at IGC's Annual Meeting of Shareholders on Oct 15'21.

IGC Announces Results of its 2021 Annual Stockholders Meeting

The stock price of India Globalization Capital, Inc. (NYSEAMERICAN: IGC) increased by over 15% pre-market. This is why it happened.

IGC Stock: Over 15% Increase Pre-Market Explanation

POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--IGC Completes its Phase 1 Clinical Trial on Alzheimer's Patients, Reports Safety and Tolerability.

IGC Completes its Phase 1 Clinical Trial on Alzheimer's Patients, Reports Safety and Tolerability

BETHESDA, Md.--(BUSINESS WIRE)-- #IGCAD1--IGC announces financial results for quarter ended Jun 30, 2021 & completion of Phase 1 clinical trial of IGC-AD1 to alleviate Alzheimer's symptoms.

IGC Reports Financial Results for the June 30, 2021, Quarter

India Globalization Capital Receives Patent To Treat Alzheimer's With Cannabis Drug

Cassava Sciences Inc

Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment.

An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Promising Treatments

India Globalization Capital (AMEX:IGC) shares are trading higher after the company announced the issuance of a patent for the treatment of Alzheimer's disease using THC.  The company was issued a patent from the United States Patent And Trademark Office titled ‘Ultra-Low Dose THC As A Potential Therapeutic And Prophylactic Agent For Alzheimer's Disease.

Why India Globalization Capital Shares Spiked Today

India Globalization Capital, Inc. (AMEX: IGC) revealed Thursday that it has obtained a patent from the United States Patent and Trademark Office for the treatment of Alzheimer's disease. The patent (#11,065,225) is named “ Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's Disease.

India Globalization Capital Shares Skyrocket On Receiving Patent For THC Formula To Treat Alzheimer's Disease

Second Sight Medical Products

Best high-volume penny stocks for your watchlist right now? Check these 4 out The post Highest Volume Penny Stocks to Watch Today?

Highest Volume Penny Stocks to Watch Today? Check These 4 Out

IGC stock is moving up in a huge way today. The company is finally earning its patent for the treatment of Alzheimer's disease with cannabis.

IGC Stock: The Huge Cannabis Patent News That Has IGC Flying High

POTOMAC, Md.--(BUSINESS WIRE)--IGC Announces Issuance of Patent for the Treatment of Alzheimer's Disease Using THC

IGC Announces Issuance of Patent for the Treatment of Alzheimer's Disease Using THC

Auddia

AYRO

Which penny stocks are investors watching with AMC back in focus? The post Top Penny Stocks To Buy Now?

Top Penny Stocks To Buy Now? 10 To Watch As AMC Volatility Continues

AFC Gamma

Arena Pharmaceuticals

Canopy Growth

Corbus Pharmaceuticals Holdings

Evogene

OrganiGram Holdings Inc.

SNDL Inc.

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials

POTOMAC, Md.--(BUSINESS WIRE)-- #IGCAD1--IGC completed Final Cohort of Phase 1 clinical trial on its THC-based investigational new drug intended to alleviate symptoms of Alzheimer's disease.

IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimer's Patients

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021.

IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Completes Cohort 2 of its Phase 1 Tetrahydrocannabinol (“THC”)-Based Investigational New Drug Clinical Trial on Alzheimer's Patients.

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients

India Globalization Capital (IGC) Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients

The stock price of India Globalization Capital, Inc. (NYSEAMERICAN: IGC) increased by 15.82%. This is why it happened.

News for India Globalization Capital Stock (IGC)